华森制药(002907) - 2020 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2020 was ¥170,526,616.65, representing a decrease of 11.04% compared to ¥191,690,822.57 in the same period last year[9]. - The net profit attributable to shareholders for Q1 2020 was ¥27,846,825.73, down 10.84% from ¥31,231,261.11 year-on-year[9]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥25,504,415.52, a decline of 17.03% compared to ¥30,738,966.13 in the previous year[9]. - The basic earnings per share for Q1 2020 was ¥0.0696, down 10.88% from ¥0.0781 in the previous year[9]. - The total operating profit for the current period is 32,386,611.92, compared to 36,830,800.13 in the previous period, reflecting a decrease of approximately 12.5%[70]. - The total comprehensive income for the current period is 27,398,316.68, down from 31,346,020.12 in the previous period, reflecting a decrease of approximately 12.5%[73]. Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥9,075,927.29, a 122.33% increase from a negative cash flow of ¥40,644,513.06 in the same period last year[9]. - The company reported a significant increase in cash flow from operating activities, with a net cash flow of 9,075,927.29, up 122.33% compared to the previous period[26]. - Cash inflow from operating activities totaled 150,568,616.49, an increase from 131,999,307.70 in the previous period, representing a growth of approximately 14%[74]. - Cash outflow from operating activities decreased to 141,492,689.20 from 172,643,820.76, showing a reduction of about 18%[77]. - The net cash flow from investment activities was -6,392,252.16, a significant improvement from -159,585,167.54 in the previous period[84]. - The company received cash from borrowings amounting to 6,000,000.00, contributing to a net cash flow from financing activities of 5,974,379.17, compared to -8,200,507.07 previously[84]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,641,061,954.69, a slight increase of 0.22% from ¥1,637,469,529.33 at the end of the previous year[9]. - The net assets attributable to shareholders increased by 2.76% to ¥1,100,373,496.24 from ¥1,070,800,378.47 at the end of the previous year[9]. - Total liabilities decreased to CNY 540,688,458.45 from CNY 566,669,150.86, a reduction of approximately 4.6%[47]. - The company's equity attributable to shareholders increased to CNY 1,100,373,496.24 from CNY 1,070,800,378.47, reflecting a growth of about 2.7%[49]. - The total amount of accounts payable is approximately 123.57 million, with other payables at about 116.30 million[94]. Government Subsidies and Other Income - The company received government subsidies amounting to ¥1,087,250.00 during the reporting period, which were included in other income[9]. - The company received government subsidies amounting to 5,504,514.10, representing a 131.36% increase compared to the previous period[21]. - The company reported a fair value change and income from financial products amounting to ¥1,820,834.85[9]. Expenses - Total operating costs for Q1 2020 were CNY 138,152,495.71, down 10.6% from CNY 154,498,342.28 year-over-year[59]. - The company reported a 32.41% decrease in sales expenses, amounting to 48,954,949.03, attributed to the inability to conduct offline academic conferences during the pandemic[23]. - Research and development expenses for Q1 2020 were CNY 4,867,581.50, down 23.6% from CNY 6,378,607.70 in the previous year[59]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 25,743, with the largest shareholder holding 46.84% of the shares[13]. - Owner's equity increased to CNY 1,101,501,025.27, up from CNY 1,072,397,866.72, representing a growth of 2.7%[57]. Changes in Financial Reporting - The company implemented new revenue recognition standards starting January 1, 2020, which may impact future financial reporting[85]. - The company has implemented new revenue recognition standards effective January 1, 2020, which may impact financial reporting[100].